Device Trial Radar · NCT06857708
The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 5, 2025
Primary completion
Sep 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Benjamin T. MillerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, pilot, parallel group, randomized controlled trial with 1:1 allocation. This will be a single center study coordinated at the Cleveland Clinic Foundation (CCF) Main Campus in Cleveland, Ohio. Data will be collected in a secure manner using REDCap housed at CCF. The study will consist of 2 arms: treatment with Cytal® Wound Matrix 2-Layer and MicroMatrix® (Integra LifeSciences, Plainsboro Township, NJ, U.S.A.) versus standard of care dressings. Wound debridement procedures will be performed by surgical staff at CCF. A co-investigator trained in the application of Cytal® Wound Matrix and MicroMatrix® will apply these treatments as outlined in section 6.1.2 Administration. This study will be conducted with IRB approval and written informed consent of each participant enrolled. The trial will be registered at ClinicalTrials.gov before the first participant is enrolled.
Conditions
- Necrotizing Fascitis
- Necrotizing Soft Tissue Infection
Interventions
Cytal® Wound MatrixDevice
This is the only study to use this intervention in necrotizing soft tissue wounds
MicroMatrix®Device
This is the only study to use this intervention in necrotizing soft tissue wounds
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to readiness for grafting of the wound bedTime frame: From randomization to readiness for grating, up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.